Get a reply from this employer
Your resume and cover letter, tailored to exactly what they’re hiring for.
IBIMA Plataforma BIONAND in Spain invites applications for a fixed-term role in translational cancer research within the Clinical Trials Unit of the IBIMA Bionand Platform, located at Virgen de la Victoria University Hospital. The role emphasizes translational cancer immunotherapy and epigenetics with a clinical trials background.
Applicants should have proven experience in clinical trials (CRA, Study Coordinator), with oncology trials in lung, melanoma, head and neck cancers, and certificates
Organisation/Company IBIMA Plataforma BIONAND Research Field Medical sciences » Health sciences Researcher Profile Other Profession Positions PhD Positions Application Deadline 22 Nov 2026 - 00:00 (Europe/Madrid) Country Spain Type of Contract Permanent Job Status Full-time Hours Per Week 35 Offer Starting Date 13 Nov 2026 Is the job funded through the EU Research Framework Programme? Other EU programme Reference Number 2026/257 Is the Job related to staff position within a Research Infrastructure? No
Reference: 2026/257
Research line description: Clinical - Translational Research in breast, prostate, gynecological, digestive, and germ cell cancers
Research line: IBIMA-B-05 TRANSLATIONAL RESEARCH IN CANCER IMMUNOTHERAPY AND EPIGENETICS
Principal Investigator: ANTONIO RUEDA DOMINGUEZ
Location: IBIMA Bionand Platform - Located at Virgen de la Victoria University Hospital, 2nd floor, Medical Oncology Clinical Trials Unit, clinical trial coordinators office
These requirements must be certified with an official certificate issued by the competent authority or a self-declaration.
Specific Requirements
Bachelor in Health Sciences: Medicine, Pharmacy, Biology.
Languages ENGLISH Level Excellent
Selection process
Based on the points obtained in the merits evaluation, at least the three best candidates will be selected for a personal interview where communication skills, work aptitude, and abilities will be assessed, with a maximum of 3 points. Only candidates who score at least 50% of the evaluable merits will be eligible for the interview stage.